{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:47Z","timestamp":1792787927422,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)","id":[{"id":"https:\/\/ror.org\/01zgy1s35","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a widely incurable B-cell malignancy that predominantly affects older adults, representing 10% of hematologic cancers. Despite advancements in therapy that have significantly extended median overall survival (OS), MM remains a clinical challenge with poor prognosis for patients refractory to multiple drug classes. There is a critical need for innovative and personalized treatments, including for patients with translocation (11;14), a subgroup characterized by specific therapeutic vulnerabilities. Combined targeting of B-cell maturation antigen (BCMA) and BCL-2 presents a promising personalized treatment strategy for inducing deep remissions and improving outcomes in this specific subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The BELI(E)VE trial (NCT05853965) is a German investigator-initiated, prospective, multicenter, open-label phase I\/IIa study designed to evaluate the combination of belantamab mafodotin and venetoclax, with or without dexamethasone, in patients with relapsed or refractory multiple myeloma (RRMM) with \u22651 prior treatment line and t(11;14) translocation. The study consists of a dose escalation phase (phase I) to determine the recommended phase 2 dose (RP2D), followed by a dose expansion phase (phase IIa) to assess clinical activity at the RP2D. The phase I portion employs a traditional 3+3 design across four dose levels, while the phase IIa expansion will include 25 additional patients treated at the RP2D. Safety, tolerability, and preliminary efficacy will be evaluated through comprehensive assessments, including assessment for minimal residual disease negativity and ocular exams.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The BELI(E)VE trial aims to establish a novel personalized therapeutic approach for a specific subset of MM patients by combining belantamab mafodotin and venetoclax. This combination targets BCMA and BCL-2, potentially inducing deep and durable remissions. The study will provide critical data on the safety and efficacy of this combination, aiming to improve outcomes in t(11;14)-positive RRMM patients. The translational component, examining circulating tumor cells and mitochondrial activity, may identify mechanisms of resistance and response, guiding future personalized therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT05853965 (2023-04-22).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16905-3","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:04:34Z","timestamp":1789560274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma \u2013 the BELI(E)VE trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Christoph","family":"Schaefers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Khandanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Alsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Kamili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Kosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Bohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias Karl","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Suling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Zapf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-588X","authenticated-orcid":false,"given":"Lisa","family":"Leypoldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"1","key":"16905_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10(1):45.","journal-title":"Nat Rev Dis Primers"},{"key":"16905_CR2","volume-title":"Blood","author":"M R\u00fcckert","year":"2024","unstructured":"R\u00fcckert M, et al. Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012\u20132023 through the Honeur Federated Data Network. Blood. San Diego, CA: American Society of Hematology; 2024."},{"issue":"5","key":"16905_CR3","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36(5):1371\u20136.","journal-title":"Leukemia"},{"issue":"9","key":"16905_CR4","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375.","journal-title":"Leukemia"},{"issue":"12","key":"16905_CR5","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1038\/s41375-024-02404-6","volume":"38","author":"MV Mateos","year":"2024","unstructured":"Mateos MV, et al. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed\/refractory multiple myeloma\u2009\u2013\u20092-year follow-up (final analysis). Leukemia. 2024;38(12):2554\u201360.","journal-title":"Leukemia"},{"issue":"1","key":"16905_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi NC, et al. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol. 2017;3(1):28\u201335.","journal-title":"JAMA Oncol"},{"issue":"6","key":"16905_CR7","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41375-020-01049-5","volume":"35","author":"K Weisel","year":"2021","unstructured":"Weisel K, et al. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. Leukemia. 2021;35(6):1732\u201344.","journal-title":"Leukemia"},{"issue":"4","key":"16905_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren O, et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. 2024;144(4):359\u201367.","journal-title":"Blood"},{"key":"16905_CR9","unstructured":"2024 Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. Available from: https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/april-12-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04122024."},{"issue":"2","key":"16905_CR10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103(2):689\u201394.","journal-title":"Blood"},{"issue":"1","key":"16905_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor BP, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199(1):91\u20138.","journal-title":"J Exp Med"},{"key":"16905_CR12","doi-asserted-by":"crossref","unstructured":"Cho S-F, Anderson KC, Tai Y-T. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Frontiers in Immunology. 2018;9:1821. Published 10 Aug 2018.","DOI":"10.3389\/fimmu.2018.01821"},{"issue":"8","key":"16905_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"6","key":"16905_CR14","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023;41(6):1265\u201374.","journal-title":"J Clin Oncol"},{"issue":"6","key":"16905_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"16905_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1182\/blood-2022-162440","volume":"140","author":"NJ Bahlis","year":"2022","unstructured":"Bahlis NJ, et al. Efficacy and Safety of Elranatamab in Patients with Relapsed\/Refractory Multiple Myeloma Na\u00efve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study. Blood. 2022;140(Supplement 1):391\u20133.","journal-title":"Blood"},{"issue":"22","key":"16905_CR17","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, et al. Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma. J Clin Oncol. 2024;42(22):2702\u201312.","journal-title":"J Clin Oncol"},{"issue":"12","key":"16905_CR18","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel S, et al. Targeting B-cell maturation antigen with GSK2857916 antibody\u2013drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19(12):1641\u201353.","journal-title":"Lancet Oncol"},{"issue":"4","key":"16905_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","volume":"9","author":"S Trudel","year":"2019","unstructured":"Trudel S, et al. Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9(4):37.","journal-title":"Blood Cancer J"},{"issue":"2","key":"16905_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207\u201321.","journal-title":"Lancet Oncol"},{"issue":"5","key":"16905_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;391(5):393\u2013407.","journal-title":"N Engl J Med"},{"issue":"5","key":"16905_CR22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, et al. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. N Engl J Med. 2024;391(5):408\u201321.","journal-title":"N Engl J Med"},{"issue":"9","key":"16905_CR23","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41375-018-0223-9","volume":"32","author":"C Touzeau","year":"2018","unstructured":"Touzeau C, et al. Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia. 2018;32(9):1899\u2013907.","journal-title":"Leukemia"},{"issue":"7","key":"16905_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"4","key":"16905_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"12","key":"16905_CR26","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630\u201342.","journal-title":"Lancet Oncol"},{"issue":"22","key":"16905_CR27","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401\u20139.","journal-title":"Blood"},{"issue":"4","key":"16905_CR28","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1200\/JCO.2000.18.4.804","volume":"18","author":"R Konigsberg","year":"2000","unstructured":"Konigsberg R, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 2000;18(4):804\u201312.","journal-title":"J Clin Oncol"},{"issue":"10","key":"16905_CR29","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","volume":"99","author":"R Fonseca","year":"2002","unstructured":"Fonseca R, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99(10):3735\u201341.","journal-title":"Blood"},{"issue":"9","key":"16905_CR30","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119(9):2100\u20135.","journal-title":"Blood"},{"issue":"4","key":"16905_CR31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajh.26083","volume":"96","author":"JL Kaufman","year":"2021","unstructured":"Kaufman JL, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma. Am J Hematol. 2021;96(4):418\u201327.","journal-title":"Am J Hematol"},{"issue":"36suppl","key":"16905_CR32","doi-asserted-by":"publisher","first-page":"439572","DOI":"10.1200\/JCO.2024.42.36_suppl.439572","volume":"42","author":"M-V Mateos","year":"2024","unstructured":"Mateos M-V, et al. Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2024;42(36suppl):439572\u2013439572.","journal-title":"J Clin Oncol"},{"issue":"22","key":"16905_CR33","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1182\/bloodadvances.2025016949","volume":"9","author":"MV Mateos","year":"2025","unstructured":"Mateos MV, et al. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025;9(22):5708\u201319.","journal-title":"Blood Adv"},{"issue":"16suppl","key":"16905_CR34","first-page":"TPS7567","volume":"43","author":"S Lonial","year":"2025","unstructured":"Lonial S, et al. Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM). J Clin Oncol. 2025;43(16suppl):TPS7567\u20137567.","journal-title":"J Clin Oncol"},{"issue":"19","key":"16905_CR35","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","volume":"5","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood Adv. 2021;5(19):3748\u201359.","journal-title":"Blood Adv"},{"issue":"3","key":"16905_CR36","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1200\/JCO-25-00924","volume":"44","author":"R Popat","year":"2026","unstructured":"Popat R, et al. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed\/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. J Clin Oncol. 2026;44(3):164\u201375.","journal-title":"J Clin Oncol"},{"issue":"32","key":"16905_CR37","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","volume":"39","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, et al. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). J Clin Oncol. 2021;39(32):3602\u201312.","journal-title":"J Clin Oncol"},{"issue":"10","key":"16905_CR38","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801\u201312.","journal-title":"Lancet Haematol"},{"issue":"16suppl","key":"16905_CR39","doi-asserted-by":"publisher","first-page":"8018","DOI":"10.1200\/JCO.2023.41.16_suppl.8018","volume":"41","author":"SZ Usmani","year":"2023","unstructured":"Usmani SZ, et al. A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9. J Clin Oncol. 2023;41(16suppl):8018\u20138018.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16905-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16905-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16905-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:02:42Z","timestamp":1790280162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16905-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16905"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16905-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"17 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The principal investigator will ensure that this study is conducted in accordance with either the current version of the Declaration of Helsinki or applicable laws and regulations. The study protocol has been written and will be implemented following the ICH Harmonized Tripartite Guideline for Good Clinical Practice (reference:\n                      \n                      ). The protocol (BELI(E)VE-Trial) has been approved by the independent ethics committee of the Medical Council Hamburg, with the processing number 2023-100993-AMG-ff. Prior to a subject\u2019s participation in the clinical study, the investigator must obtain written informed consent from the participant. All subjects will receive information regarding the study\u2019s objectives, potential adverse events, anticipated benefits, and procedures. They will also be informed about possible hazards, the treatment allocation mechanism, and alternative treatment options. Additionally, subjects will be briefed on their insurance coverage and any obligations associated with their insurance.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Competing interests. C.S.: Consultancy for Acus Health, Astra Zeneca, Janssen-Cilag, Oncopeptides, Pfizer; honoraria from Abbvie, Astra Zeneca, Janssen-Cilag; other: Acus Health (travel expenses), Menarini Stemline (travel expenses), Oncopeptides (travel ex-penses), Sanofi (travel expenses)C.K.: Consultancy for Abbvie and GSKM.H.: Consultancy for Amgen, Bayer, Bristol Myers Squibb, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Incyte, Janssen, Jazz Pharmaceuticals, Kite\/Gilead, Pfizer, Roche, Sanofi-Aventis, Takeda, Sobi; Honoraria from Bristol Myers Squibb, Falk, Gilead, Kite\/Gilead, Novartis, Sobi; Membership on an entity\u2019s Board of Directors or advisory committees: Amgen, Bayer, Bristol Myers Squibb, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Incyte, Janssen, Jazz Pharmaceu-ticals, Kite\/Gilead, Pfizer, Roche, Sanofi-Aventis, SobiM.K.: nothing to discloseW.A.: Consultancy: Janssen, Honoraria from GSK, AstraZeneca, Astellas, Janssen, research funding (received by institution): Affimed, Biontech, other (travel accomo-dations expenses): Biontech, Immatics, Janssen, A.K.: Consultancy, travel expenses and honoraria from Janssen-CilagR.K.: Travel grants from AmgenW.K.: nothing to discloseS.B.: nothing to discloseE.K.M.: Consulting or advisory role for Amgen, Bristol Myers Squibb\/Celgene, Glax-oSmithKline, Janssen-Cilag, Oncopeptides, Pfizer, Sanofi, Stemline and Takeda. Honoraria from Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Oncopeptides, Pfizer, Sanofi, Stemline and Takeda. Research funding from Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi and Takeda . Travel accommodations and expenses from Bristol Myers Squibb\/Celgene, Glax-oSmithKline, Janssen-Cilag, Sanofi, Stemline and Takeda. C.Sch.: Honoraria from Amgen, BMS, Celgene, GSK, Janssen, Novar-tis, Oncopeptides, Pfizer, Roche, Sanofi, Stemline, Takeda; Research support from Janssen, Takeda, Novartis. H.E.: Consultancy for Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen, Novartis, Sanofi, Takeda; Honoria and Travel Support from Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen, Novartis, Sanofi, Takeda M.B.: Research support and consultancy fees from Amgen; speakers\u2019 bureaus for Amgen, Becton Dickinson, Janssen, and Pfizer; support for travel from Janssen; and membership of advisory boards for Amgen and Incyte A.S.: nothing to disclose A.Z.: nothing to disclose C.B.: Consultancy for AOK Germany, AstraZeneca, Bayer Healthcare, BioNTech, Lindis Biotech, Sanofi Aventis; Honoraria from med update, Merck Serono, Roche Pharma.K.W.: Consultancy for AbbVie, Adaptive Biotech, Amgen, BeiGene, GSK, Johnson and Johnson \u2013 Janssen, Karyopharm, Menarini, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Takeda; Honoraria from AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Bristol Myers Squibb\/Celgene, Celgene, GSK, Janssen, No-vartis, Oncopeptides, Sanofi, Stemline, Takeda; Membership on an entity\u2019s Board of Directors or advisory committees for AbbVie, Adaptive Biotech, Amgen, BeiGene, Bristol Myers Squibb, Bristol Myers Squibb\/Celgene, Celgene, GSK, Johnson and Johnson \u2013 Janssen, Karyopharm, Menarini, Novartis, Oncopeptides, Pfizer, Re-generon, Roche, Sanofi, Takeda; Research Funding: AbbVie, Amgen, GSK, John-son and Johnson \u2013 Janssen, Pfizer, Bristol Myers Squibb\/Celgene, Novartis, Sano-fi, TakedaL.L.: Consultancy for GSK, Sanofi, Janssen; honoraria from Adaptive, AbbVie, Janssen, BMS\/Celgene, Pfizer, Sanofi, GSK; research funding from Abbvie, GSK (both to the institution); other (travel expenses): Sanofi, Oncopeptides.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1141"}}